NCT00526968View on ClinicalTrials.gov

The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Human Volunteers
Interventions
DRUG

EVT 101

8 mg capsule, single oral dose

DRUG

EVT 101

15 mg capsule, single oral dose

DRUG

placebo

Placebo capsule, single oral dose

Trial Locations (1)

SE5 8AF

Centre for Neuroimaging Science, Box 089, Institute of Psychiatry, London

Sponsors
All Listed Sponsors
collaborator

Richmond Pharmacology Limited

INDUSTRY

lead

Evotec Neurosciences GmbH

INDUSTRY